Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSHUA A WHATLEY

Allopathic & Osteopathic Physicians Family Medicine

NPI
1386961787
CMS profile
335838
Location
LAKE CHARLES, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,196.01

133 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,196.01 133

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 3; records 1–50 of 133 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSHUA A WHATLEY

NPI 1386961787 · CMS profile ID 335838

Allopathic & Osteopathic Physicians / Family Medicine

LAKE CHARLES, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 133 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386961787?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSHUA A WHATLEY, NPI 1386961787, CMS profile ID 335838. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 133 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386961787?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOSHUA A WHATLEY, NPI 1386961787, CMS profile ID 335838. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 133 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386961787?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOSHUA A WHATLEY, NPI 1386961787, CMS profile ID 335838, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 133 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1386961787?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

133 matching records · $2,196.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 133 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 133.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $16.8712/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018748541 CMS
Amgen Inc. $10.9512/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020610325 CMS
Lilly USA, LLC $20.7012/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031540753 CMS
Novartis Pharmaceuticals Corporation $0.3612/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993259347 CMS
Novartis Pharmaceuticals Corporation $13.7912/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993259349 CMS
GlaxoSmithKline, LLC. $27.6811/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003262351 CMS
Amgen Inc. $15.3111/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019980011 CMS
Novo Nordisk Inc $22.3511/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000385471 CMS
PFIZER INC. $5.0011/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050596197 CMS
Novartis Pharmaceuticals Corporation $35.1111/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993425059 CMS
PFIZER INC. $20.9910/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049675823 CMS
GlaxoSmithKline, LLC. $17.2410/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003260773 CMS
Lilly USA, LLC $14.3210/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031645767 CMS
Novo Nordisk Inc $9.8010/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000385413 CMS
PFIZER INC. $5.9910/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050574035 CMS
GlaxoSmithKline, LLC. $25.0410/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003261571 CMS
Lilly USA, LLC $21.5710/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031582729 CMS
Novo Nordisk Inc $10.7810/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000385423 CMS
Amgen Inc. $19.0710/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019980009 CMS
AbbVie Inc. $18.1310/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999604755 CMS
Novartis Pharmaceuticals Corporation $17.2410/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993259345 CMS
Astellas Pharma US Inc $18.8310/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034572551 CMS
Merck Sharp & Dohme LLC $16.5410/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048430653 CMS
AbbVie Inc. $19.5309/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999604749 CMS
GlaxoSmithKline, LLC. $18.7709/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003263807 CMS
PFIZER INC. $18.9909/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050539355 CMS
GlaxoSmithKline, LLC. $24.9109/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003262347 CMS
Amgen Inc. $11.0209/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020610323 CMS
PFIZER INC. $23.0209/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049392007 CMS
Novartis Pharmaceuticals Corporation $15.3609/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993259343 CMS
Amgen Inc. $15.2809/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019980007 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.2309/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057479732 CMS
Novo Nordisk Inc $15.5108/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000385453 CMS
AstraZeneca Pharmaceuticals LP $18.8408/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015325157 CMS
AbbVie Inc. $7.4808/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999604744 CMS
Astellas Pharma US Inc $18.8308/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034440839 CMS
Lilly USA, LLC $14.6408/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031645779 CMS
AbbVie Inc. $33.1608/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999604739 CMS
Novo Nordisk Inc $14.9108/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000385447 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.4408/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000070509 CMS
Amgen Inc. $12.4708/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019980005 CMS
AbbVie Inc. $16.3908/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999604731 CMS
PFIZER INC. $19.8508/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050559149 CMS
Abbott Laboratories $17.0008/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018705907 CMS
Currax Pharmaceuticals LLC $13.2808/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 986425091 CMS
Novo Nordisk Inc $11.9408/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000385435 CMS
AbbVie Inc. $8.2507/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999604727 CMS
Axsome Therapeutics, Inc. $24.5307/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056169927 CMS
AstraZeneca Pharmaceuticals LP $9.8907/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015780457 CMS
Astellas Pharma US Inc $19.8807/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034300937 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,052.70 165
PY2020 $1,613.01 107
PY2021 $3,626.66 165
PY2022 $2,624.95 158
PY2023 $2,196.01 133
PY2024 $2,213.51 134
PY2025 $2,340.57 130

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $163.24 1
PY2023 Principal investigator $22,600.32 6
PY2022 Principal investigator $180,941.31 164
PY2021 Principal investigator $125,292.52 151
PY2020 Principal investigator $20,750.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

151 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828418031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828418033
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828418077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418079
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828418085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828418087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828418089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828418269
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828418271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828418273
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828418275
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828418277
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418279
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418281
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418283
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418285
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418287
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418289
Principal investigator 1 AstraZeneca Pharmaceuticals LP $269.67 12/31/2021 Non-covered Recipient Entity
CENTEX STUDIES, INC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 826489347
Principal investigator 1 ABBVIE INC. $16.90 12/30/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792488703
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,725.00 12/22/2021 Non-covered Recipient Entity
CENTEX STUDIES INC
AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C No dispute reported 06/30/2026 965470175
Principal investigator 1 Kowa Research Institute, Inc. $241.20 12/21/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
K-877-302 No dispute reported 06/30/2026 771714422
Principal investigator 1 ABBVIE INC. $200.00 12/15/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792487027
Principal investigator 1 ABBVIE INC. $71.12 12/15/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792487029
Principal investigator 1 Janssen Pharmaceuticals, Inc $86.00 12/15/2021 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787570117
Principal investigator 1 Janssen Pharmaceuticals, Inc $270.00 12/15/2021 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787570127
Principal investigator 1 Janssen Pharmaceuticals, Inc $696.00 12/15/2021 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787570149
Principal investigator 1 ABBVIE INC. $2,818.58 12/09/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792486215
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,892.00 12/08/2021 Non-covered Recipient Entity
C1 Headlands LLC
POCC in NASH No dispute reported 06/30/2026 840492995
Principal investigator 1 Janssen Pharmaceuticals, Inc $630.00 12/08/2021 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787570139
Principal investigator 1 Janssen Pharmaceuticals, Inc $837.00 12/08/2021 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787570161
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,392.00 12/08/2021 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787570171
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,995.00 12/08/2021 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787570183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 12/05/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418017
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 12/05/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418019
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 12/05/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418021
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 12/05/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 12/05/2021 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828418037
Principal investigator 1 Kowa Research Institute, Inc. $1,575.00 12/01/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
K-877-302 No dispute reported 06/30/2026 771714420
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418027
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418029
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418059
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418065
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418071
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418073
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418075
Principal investigator 1 ABBVIE INC. $33.80 11/24/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792484193
Principal investigator 1 ABBVIE INC. $33.80 11/24/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792484195
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,640.00 11/24/2021 Non-covered Recipient Entity
CENTEX STUDIES, INC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 826492905
Principal investigator 1 ABBVIE INC. $107.95 11/09/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792481811
Principal investigator 1 Kowa Research Institute, Inc. $120.00 11/05/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
K-877-302 No dispute reported 06/30/2026 771714418
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $51.14 11/01/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386315
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418023
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/29/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418039
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/29/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418041
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418053
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418057
Principal investigator 1 Kowa Research Institute, Inc. $241.20 10/22/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
K-877-302 No dispute reported 06/30/2026 771714416
Principal investigator 1 ABBVIE INC. $71.12 10/20/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792480045
Principal investigator 1 Janssen Pharmaceuticals, Inc $30,233.00 10/20/2021 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787570205
Principal investigator 1 Janssen Pharmaceuticals, Inc $3,480.00 10/13/2021 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787570193
Principal investigator 1 ABBVIE INC. $5,951.03 10/07/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792478077
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $51.22 10/01/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386317
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417923
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417987
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417993
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417999
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828418005
Principal investigator 1 ABBVIE INC. $200.00 09/29/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792476611
Principal investigator 1 ABBVIE INC. $100.00 09/29/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792476613
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $10.00 09/27/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386327
Principal investigator 1 Kowa Research Institute, Inc. $2,644.20 09/27/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
K-877-302 No dispute reported 06/30/2026 771713528
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,312.80 09/24/2021 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787570105
Principal investigator 1 Kowa Research Institute, Inc. $60.00 09/24/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
K-877-302 No dispute reported 06/30/2026 771713526
Principal investigator 1 ABBVIE INC. $24.00 09/23/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792476195
Principal investigator 1 Janssen Pharmaceuticals, Inc $29,059.00 09/22/2021 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787570095
Principal investigator 1 Kowa Research Institute, Inc. $75.00 09/17/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
K-877-302 No dispute reported 06/30/2026 771713524
Principal investigator 1 ABBVIE INC. $801.79 09/08/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792474261
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $52.26 09/01/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386333
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $44.40 09/01/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386335
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $483.00 09/01/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386337
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417917
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417919
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417949
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417957
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417961
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417963
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417965
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $52.52 08/01/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386331
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417905
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417925
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417939
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 07/27/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 07/27/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417911
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 07/27/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $70.00 07/27/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 07/27/2021 Non-covered Recipient Entity
Centex Studies Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828417945
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $114.00 07/27/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386325
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $52.46 07/01/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386319
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $10.50 06/24/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386321
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $486.57 06/18/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386301
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $24.60 06/06/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386303
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $10.80 06/06/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386305
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $62.50 06/06/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386307
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $133.00 06/06/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386309
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $69.00 06/06/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386311
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $14.80 06/06/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386313
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $1,385.64 05/26/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386297
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $125.00 05/14/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386291
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $125.00 05/14/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386341
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $25.00 05/14/2021 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 828386343
Principal investigator 1 ABBVIE INC. $62.23 03/29/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792435967
Principal investigator 1 ABBVIE INC. $65.00 01/12/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792408697
Principal investigator 1 ABBVIE INC. $100.00 01/07/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792407961
Principal investigator 1 ABBVIE INC. $842.91 01/06/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792407651
Principal investigator 1 ABBVIE INC. $65.00 01/05/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792407323
Principal investigator 1 ABBVIE INC. $2,238.81 01/05/2021 Non-covered Recipient Entity
C-1 HEADLANDS LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792407329